• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

DoxyPEP: A “Morning After” Pill For STIs Could Be On The Horizon

March 30, 2024 by Deborah Bloomfield

Preventing the spread of some sexually transmitted infections (STIs) could be as simple as taking a couple of pills. At least, this is a possible scenario if DoxyPEP becomes more widely available worldwide. The treatment uses an antibiotic as a post-exposure prophylaxis – a preventative treatment that can stop the spread of bacterial infection.

Research on this approach is limited, but it has shown early positive results. So much so, in fact, that the US Centers for Disease Control and Prevention proposed guidelines for its use in October 2023, although these are yet to be finalized.

Advertisement

“DoxyPEP is what people commonly call it, but ‘doxycycline post-exposure prophylaxis’ in full is when people take 200 milligrams of doxycycline, which is an antibiotic, and they take it usually within 24 hours, but up to 72 hours of condomless sex,” Dr Manik Kohli, a Clinical Research Fellow at the UCL Institute for Global Health, told IFLScience. “This has been shown in three clinical trials to be effective in gay and bisexual men and in transgender women at preventing chlamydia, syphilis, and gonorrhea as well.”

Scientists see no reason why those results wouldn’t apply to everyone, but medical interventions require rigorous trials and so far those trials have included just a small section of people. 

“We still don’t know enough about DoxyPEP efficacy in cisgender women, trans men, and non-binary people with vaginas. There’s only one existing study in cisgender women in Kenya, and the data from that was sort of mixed – it showed that DoxyPEP didn’t work as well. But there are also some suggestions that that was because the women in the study weren’t taking DoxyPEP as regularly as other people in other studies,” Dr Ben Weil, head of research and community knowledge generation at The Love Tank, told IFLScience.

More clinical trials are being conducted around the world and preliminary results suggest a reduction in the incidence of chlamydia and syphilis by over 80 percent. But the most interesting interim results come from real-world data from the San Francisco AIDS Foundation’s Magnet sexual health clinic. Dr Hyman Scott, who presented the results at the recent Conference on Retrovirus and Opportunistic Infections, reports how the clinic offered DoxyPEP to everyone who was already taking PrEP (pre-exposure prophylaxis) against HIV.

Advertisement

“We offered DoxyPEP to all those folks. We wanted to evaluate the impact of this intervention after we rolled it out in our clinic,” Dr Scott explained to IFLScience, “and we saw that the impact was rapid and it was significant.”

Three packets of antibitioic Doxycycline on a table.

A small dose of this antibiotic might be a way to prevent STIs.

Image credit: Cliff Day/Shutterstock.com

There are now over 2,000 people who are currently using DoxyPEP for STI prevention and the uptake is generally equitable across race, ethnicity, and gender identities, although fewer trans men and no cisgender women were taking it at the time of writing. This is related to the lack of clinical trials including them. The results, though, are extremely promising.

“We saw a 58 percent reduction in STI incidents in less than a year after implementing this,” Dr Scott told IFLScience. “That’s the big highlight for what we saw in this analysis, and that number was a reduction in any STI. It was most dramatic for syphilis, where we saw a 78 percent reduction and we saw a 67 percent reduction for chlamydia.”

The reduction in gonorrhea cases was more modest (11 percent) but it might be possible that the downward trend is not as rapid as with the other two diseases. All of this is extremely encouraging, but researchers hope for more studies that can provide further insight into the effectiveness across different populations and at different doses and regimens.

Advertisement

“The research that exists does show that DoxyPEP is efficacious at preventing bacterial STIs, but the evidence is limited. I mean, there haven’t been that many studies, and there aren’t that many studies that have looked at more flexible dosing regimens,” Dr Weil told IFLScience.

“Just like with HIV prep or any kind of contraception, we know that the more options there are available in the ways of taking an intervention, the better it is because it can meet people who have flexible lifestyles and want to take things very, very differently.”

Another area of interest is if the use of doxycycline becomes more widespread, could that cause antibiotic resistance? Some preliminary studies are leaning towards no, and suggest it definitely won’t impact bacterial STIs, but there are questions to be asked about the bacterial colonies that live within us and on us.

“That is something that we definitely want to [and] need to understand more about. I don’t think that means that we should delay implementing DoxyPEP,” Dr Kohli told IFLScience. “DoxyPEP is evidence-based and it is efficacious. We’re currently seeing STI rates rising across the board and we’re seeing congenital syphilis rising for the first time in decades. So there is a real need to actually address that.” 

Advertisement

Although the evidence so far looks promising, it’s important to note that even if DoxyPEP is implemented tomorrow, STI prevention is not just a matter of drugs. Stigma, inequalities, sexual and racial discrimination, limited funding for sexual health clinics, and the availability of interventions and education for different groups all make it more difficult to stop the spread of these diseases, which harms individuals and society as a whole.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. ARK Invest’s Wood expects market rotation back to growth stocks
  2. Most Plant-Based Milks Are Poorer In Key Micronutrients Than Dairy
  3. The Physicist And Mathematician Who Claims He Can Beat Roulette
  4. Only 1 Percent Of Chemicals Have Been Discovered – How Can We Find The Rest?

Source Link: DoxyPEP: A “Morning After” Pill For STIs Could Be On The Horizon

Filed Under: News

Primary Sidebar

  • Unethical Experiments: When Scientists Really Should Have Stopped What They Were Doing Immediately
  • The First Humans Were Hunted By Leopards And Weren’t The Apex Predators We Thought They Were
  • Earth’s Passage Through The Galaxy Might Be Written In Its Rocks
  • What Is An Einstein Cross – And Why Is The Latest One Such A Unique Find?
  • If We Found Life On Mars, What Would That Mean For The Fermi Paradox And The Great Filter?
  • The Longest Living Mammals Are Giants That Live Up To 200 Years In The Icy Arctic
  • Entirely New Virus Detected In Bat Urine, And It’s Only The 4th Of Its Kind Ever Isolated
  • The First Ever Full Asteroid History: From Its Doomed Discovery To Collecting Its Meteorites
  • World’s Oldest Pachycephalosaur Fossil Pushes Back These Dinosaurs’ Emergence By 15 Million Years
  • The Hole In The Ozone Layer Is Healing And On Track For Full Recovery In The 21st Century, Thanks To Science
  • First Sweet Potato Genome Reveals They’re Hybrids With A Puzzling Past And 6 Sets Of Chromosomes
  • Why Is The Top Of Canada So Sparsely Populated? Meet The “Canadian Shield”
  • Humans Are In The Middle Of “A Great Evolutionary Transition”, New Paper Claims
  • Why Do Some Toilets Have Two Flush Buttons?
  • 130-Year-Old Butter Additive Discovered In Danish Basement Contains Bacteria From The 1890s
  • Prehistoric Humans Made Necklaces From Marine Mollusk Fossils 20,000 Years Ago
  • Zond 5: In 1968 Two Soviet Steppe Tortoises Beat Humans To Orbiting Around The Moon
  • Why Cats Adapted This Defense Mechanism From Snakes
  • Mother Orca Seen Carrying Dead Calf Once Again On Washington Coast
  • A Busy Spider Season Is Brewing: Why This Fall Could See A Boom Of Arachnid Activity
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version